Abstract
Selegiline, an irreversible inhibitor of monoamine oxidase B (MAO B), was introduced as a symptomatic treatment for Parkinson’s disease (PD) in the mid-1970s, with the intention of enhancing the effect of levodopa (LD).1–3
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliography
Birkmayer W, Riederer P, Ambrozi L, et al. Implications of combined treatment with “Madopar” and L- deprenyl in Parkinson’s disease. Lancet 1977;1:439–43.
Lees AJ, Shaw KM, Kohout LT, et al. Deprenyl in Parkinson’s disease. Lancet 1997;2:791–5.
Streifler M, Vardi J, Borenstein N, et al. S. B-type Monoamine oxidase (M.A.O.) inhibitors in long-term levodopa treated Parkinsonism. A combined clinical trial with L-deprenyl. Curr Ther Res Clin Exp 1980;27:643–8.
Lees AJ, on behalf of the Parkinsonian’s Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311:1602–7.
Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effects of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 1998;51:825–30.
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:22228–234.
Reynold GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6: 542–4.
Gill JR, Mason DT, Bartter FC. Effects of hydroxyamphetamine (paredrine) on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther 1967;155:288–95.
Cavanaugh JH, Griffith JD, Oates JA. Effects of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man. Clin Pharmacol Ther 1970;11:656–64.
Waldmeier PC, Feiner AE. Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801–2.
Gelowitz DL, Richardson JS, Wishart TB, et al. Chronic L-, deprenyl or L- amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 1994;47:41–5.
Goodman Gilman A, Goodman LS, Rail TW, et al, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed. New York: Macmillan Publishing Company, 1985:1786.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rabey, J.M., Stryjer, R.O. (2002). The Effect of Acute Loading with Selegiline and Selegiline with Levodopa on Blood Pressure and Plasma Norepinephrine Levels in Chronic Parkinsonian Patients. In: Nagatsu, T., Nabeshima, T., McCarty, R., Goldstein, D.S. (eds) Catecholamine Research. Advances in Behavioral Biology, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3538-3_115
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3538-3_115
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-3388-1
Online ISBN: 978-1-4757-3538-3
eBook Packages: Springer Book Archive